Reuters Events | Pharma

Thought leadership and innovation for the Pharmaceutical Industry

Boehringer Ingelheim and Aptus Health take home esteemed accolade for their Interactive Guidelines Asset: GINA project

By Adam Chapman on Mar 22, 2019

It is a truth universally acknowledged that HCPs are up to their eyeballs in patient consultations. The winner of the Most Valuable HCP Initiative at our annual European awards in Barcelona last week sent a clear message to the HCP community: pharma is here to help.

Boehringer Ingelheim, in collaboration with its digital partner Aptus Health, has created a way to provide HCPs with a concise summary of the latest Global Institute for Asthma (GINA) GINA recommendations, as well as local treatment guidelines, in an interactive way that is informative and respectful of their busy schedules. The collaboration is striving to empower evidence-based decisions and support HCPs in the daily management of asthma patients.

GINA guidelines are an important contribution to the asthma community. Through this educational, interactive asset, HCPs can familiarize themselves with the clinical content and recommendations in a way that is easy to use and time-sensitive. The asset is designed to help guide the HCP through the content through a range of modules, bringing the content to life through technology.

Reflecting on the significance of the award, the team said: “It gives people real visibility. It is rare. What we presented at this award was a full programme and we gave full insights and transparency — we showed the data as well, so bringing that to the eyeforpharma platform allows other pharma members here to think about what they can achieve.”

This initiative is one of many Boehringer Ingelheim has launched over the last couple of years to help support HCPS and patients. The team let us in on the company's guiding philosophy: “What we have taken into our hearts from the beginning of the journey is really understanding our customers — the physicians and patients; what is important to them from the perspective of disease management; if we are communicating online; what are their preferences; how do they want and need to consume complex information?”

The interactive asset was deployed in a number of markets and has proven to be one of the most popular assets rolled out by the brand team to date. The most frequently selected option by the users is the 20-minute version, suggesting that HCPs find the offering appealing and valuable to them.

The partnership was selected by a judging panel of pharma industry experts, patients and customers as delivering tangible working and healthcare improvements both in the long and short term.

The other finalists for the award were:

Vision for a brighter future for people suffering with retinal disease— Committed to transforming the lives of people patients suffering with retinal disease, Bayer established the Vision Academy – which will improve how retinal disease is managed to make a positive difference to patients’ lives.

Virtual Cardio Academy — Ecopharm organised a nation-wide year-long Virtual Cardio Academy which consisted of 10 virtual events on cardiological topics with 4878 participants, led by national Key Opinion Leaders (KOLs) in Bulgaria, using the digital tools offered by cloud-based platform CredoWeb.

Bridge Project — To advance research into disease management, Menarini launched the ‘Bridge Project’ to observe and understand how different patients and physicians perceive Stable Angina(SA) and the impact of SA on QoL (Quality of Life).

Optimising IBD care through digitalization and reinforced patient empowerment— Takeda has co-created together with hospitals and the IT company Bestor, an algorithm-based platform that utilizes real time data provided by EMRs, disease registries and by patients in their home environment themselves, giving them a more active role in managing their disease.

You can find out about our upcoming North American awards here